Ignite Creation Date:
2024-05-06 @ 4:29 PM
Last Modification Date:
2024-10-26 @ 2:11 PM
Study NCT ID:
NCT05001139
Status:
COMPLETED
Last Update Posted:
2023-06-22
First Post:
2021-08-04
Brief Title:
Clinical Investigation on the Efficacy and Safety of Relizema Ecofoam
Sponsor:
Relife Srl
Organization:
Relife Srl
Study Overview
Official Title:
A Multicenter Open Label Uncontrolled Study for the Evaluation of Efficacy and Safety by Clinical Parameters of Relizema Ecofoam in Adult Atopic and Contact Dermatitis
Status:
COMPLETED
Status Verified Date:
2022-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The scope of this open label clinical trial is to evaluate and confirm the performance of Relizema ecofoam in the improvement of the dermatitis severity The disease severity will be clinically measured through the Investigator Global Assessment IGA after 28 days of treatment
Detailed Description:
The scope of this open label clinical trial is to evaluate and confirm the performance of Relizema ecofoam in the improvement of the dermatitis severity by alleviating the symptomatology The product will be applied for 42 days of treatment 2 times per day into the face
The dermatologist will perform 3 clinical follow up visits to assess the efficacy and safety of the product
The dermatologist will perform 3 clinical follow up visits to assess the efficacy and safety of the product
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None